慢性乙型肝炎病毒感染的现有及潜在治疗方法综述
Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection.
作者信息
Tsai Eugenia
机构信息
Texas Liver Institute and UT Health San Antonio, San Antonio, Texas.
出版信息
Gastroenterol Hepatol (N Y). 2021 Aug;17(8):367-376.
Abstract
Chronic hepatitis B virus (HBV) infection remains a major global health burden. Millions of people are at risk for complications of chronic HBV infection, despite the widespread availability of an effective prophylactic vaccine. The current available treatments for HBV infection-interferon and nucleos(t)ide analogues-are effective at suppressing viral replication and decreasing the risk of cirrhosis. However, these treatments have a number of limitations, creating the need for alternative therapeutic agents. Recent advances in drug therapy have heralded a new horizon of novel therapeutic approaches for chronic HBV infection, with several promising antiviral and immunomodulatory agents currently in preclinical or clinical testing. This article reviews the current landscape of HBV treatments and highlights the most recent therapeutic strategies designed to directly target HBV or to improve immune response during chronic infection.
摘要
慢性乙型肝炎病毒（HBV）感染仍然是一项重大的全球健康负担。尽管有效预防性疫苗已广泛可得，但仍有数百万人面临慢性HBV感染并发症的风险。目前可用于治疗HBV感染的药物——干扰素和核苷（酸）类似物——在抑制病毒复制和降低肝硬化风险方面是有效的。然而，这些治疗方法存在一些局限性，因此需要替代治疗药物。药物治疗的最新进展为慢性HBV感染的新型治疗方法开辟了新视野，目前有几种有前景的抗病毒和免疫调节药物正处于临床前或临床试验阶段。本文综述了HBV治疗的现状，并重点介绍了旨在直接靶向HBV或改善慢性感染期间免疫反应的最新治疗策略。
相似文献
1
Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection.
Gastroenterol Hepatol (N Y). 2021 Aug;17(8):367-376.
2
Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies.
Curr Top Med Chem. 2023;23(18):1727-1752. doi: 10.2174/1568026623666230413094331.
3
Latest developments in the treatment of hepatitis B.
Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8.
4
Aiming for cure in HBV and HDV infection.
J Hepatol. 2016 Oct;65(4):835-848. doi: 10.1016/j.jhep.2016.05.043. Epub 2016 Jun 3.
5
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10.
6
Update on hepatitis B virus infection.
World J Gastroenterol. 2014 Oct 7;20(37):13293-305. doi: 10.3748/wjg.v20.i37.13293.
7
Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Neth J Med. 2008 Jul-Aug;66(7):292-306.
8
Recent Advances in Hepatitis B Treatment.
Pharmaceuticals (Basel). 2021 May 1;14(5):417. doi: 10.3390/ph14050417.
9
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14.
10
Management of viral hepatitis B.
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S125-45. doi: 10.1046/j.1440-1746.17.s1.3.x.
引用本文的文献
1
Tenofovir disoproxil fumarate: safe and effective option for managing high-viral-load chronic hepatitis B.
Am J Transl Res. 2025 Apr 15;17(4):3228-3234. doi: 10.62347/OCYR8437. eCollection 2025.
2
Clinical effectiveness of entecavir versus tenofovir disoproxil fumarate tablets in chronic hepatitis B treatment.
Am J Transl Res. 2024 Dec 15;16(12):7591-7599. doi: 10.62347/RKNH8649. eCollection 2024.
3
Increased QPCT gene expression by the hepatitis B virus promotes HBV replication.
PLoS One. 2024 Nov 12;19(11):e0312773. doi: 10.1371/journal.pone.0312773. eCollection 2024.
4
Small Molecule Drugs Targeting Viral Polymerases.
Pharmaceuticals (Basel). 2024 May 20;17(5):661. doi: 10.3390/ph17050661.
5
Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future.
J Clin Med. 2024 Apr 2;13(7):2055. doi: 10.3390/jcm13072055.
6
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review.
Viruses. 2023 Dec 8;15(12):2395. doi: 10.3390/v15122395.
7
EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections.
Curr Med Chem. 2024;31(35):5670-5701. doi: 10.2174/0109298673256638231003111234.
8
Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.
Int J Mol Sci. 2023 May 8;24(9):8454. doi: 10.3390/ijms24098454.
9
Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection.
Vaccines (Basel). 2022 Sep 30;10(10):1644. doi: 10.3390/vaccines10101644.
10
Exploration of new therapeutic targets for viral hepatic fibrosis, alcoholic hepatic fibrosis, and non-alcoholic hepatic fibrosis.
Ann Transl Med. 2022 Aug;10(16):886. doi: 10.21037/atm-22-3593.
本文引用的文献
1
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.
Int J Mol Sci. 2021 Feb 1;22(3):1456. doi: 10.3390/ijms22031456.
2
Hepatitis B Virus Cure: Targets and Future Therapies.
Int J Mol Sci. 2020 Dec 28;22(1):213. doi: 10.3390/ijms22010213.
3
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01463-20.
4
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection.
Viruses. 2020 Aug 4;12(8):851. doi: 10.3390/v12080851.
5
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Am J Gastroenterol. 2020 Aug;115(8):1217-1225. doi: 10.14309/ajg.0000000000000605.
6
Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.
J Gastroenterol. 2020 May;55(5):496-514. doi: 10.1007/s00535-020-01680-0. Epub 2020 Mar 17.
7
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Gastroenterology. 2020 Jun;158(8):2180-2194. doi: 10.1053/j.gastro.2020.02.058. Epub 2020 Mar 6.
8
Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Antiviral Res. 2020 Feb;174:104693. doi: 10.1016/j.antiviral.2019.104693. Epub 2019 Dec 13.
9
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. doi: 10.1016/S2468-1253(19)30346-2. Epub 2019 Nov 9.
10
A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection.
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01440-19.
Zotero 插件